Peter Scheer

Multiobjective Engineering of Fibrin-Selective Thrombolytic Proteases with Enhanced Biocatalytic Efficiency and Inhibition Resistance

Abstract Thrombolytic enzymes represent an important class of proteolytic biocatalysts for medical applications, yet currently used FDA-approved variants, including alteplase and tenecteplase, remain limited by suboptimal catalytic efficiency, off-target activity, and susceptibil...